An advisory panel recommended that the FDA approve rivaroxaban, a challenger to the current industry leader in the prevention of blood clots in veins, warfarin, according to a report in the New York Times.
GLP-1s
After an extensive evidence review, CMS has announced a proposal to revise its existing coverage policy for bariatric surgery to include type 2 diabetes as one of the co-morbidities CMS would consider in determining whether bariatric surgery would be covered…
Here are 10 interesting cost figures, facts and statistics to know bariatrics and handling obese patients, from a survey conducted by group purchasing organization Novation.